false 0001158895 0001158895 2021-04-29 2021-04-29
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  April 29, 2021
 
LeMaitre Vascular, Inc.
(Exact name of registrant as specified in its charter)
 
Commission File Number:  001-33092
 
Delaware
 
04-2825458
(State or other jurisdiction of
 
(IRS Employer
incorporation)
 
Identification No.)
 
63 Second Avenue
Burlington, MA 01803
(Address of principal executive offices, including zip code)
 
781-221-2266
(Registrants telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by checkmark whether the company is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12c-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading symbol
Name of exchange on which registered
Common stock, $0.01 par value per share
LMAT 
The Nasdaq Global Market
 
 

 
Item 2.02. Results of Operations and Financial Condition.
 
On April 29, 2021, LeMaitre Vascular, Inc. (the “Company”) issued a press release regarding its preliminary financial and operational results for the quarter ended March 31, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Report.
 
The information in this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
 
 
Item 9.01. Financial Statements and Exhibits.
 
 
The following exhibits are furnished or filed as part of this Report, as applicable:
 
 
(d)
Exhibits.
 
Exhibit No.
Description
   
99.1
Press release issued by LeMaitre Vascular, Inc. on April 29, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
Exhibit Index
   
Exhibit No.
Description
   
99.1
Press release issued by LeMaitre Vascular, Inc. on April 29, 2021.
 
 

 
 
Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    LeMaitre Vascular, Inc.  
Date: April 29, 2021 By: Joseph P. Pellegrino, Jr.  
 
/s/     JOSEPH P. PELLEGRINO, JR.   
Joseph P. Pellegrino, Jr.
Chief Financial Officer